Cartesian Therapeutics Q2 FY26 net income slips 0.74% to $15.8 million

PUBT · 2d ago
Cartesian Therapeutics Q2 FY26 net income slips 0.74% to $15.8 million
  • Cartesian Therapeutics posted Q2 net income of USD 15.8 million, down 0.7% year over year; GAAP EPS slipped to USD 0.47 from USD 0.51.
  • R&D spending climbed 37% to USD 20.4 million; G&A rose 20.8% to USD 8.7 million.
  • Cash, cash equivalents and restricted cash totaled USD 149.3 million at June 30, 2026, expected to fund operations into 2028.
  • Phase 3 AURORA trial in myasthenia gravis advanced, with data expected in 1Q27; BLA filing targeted for mid-2027.
  • WestGene in vivo MG Phase 1 trial expected to start in 2H26 with data in 1H27; Phase 2 TRITON and pediatric HELIOS readouts slated for 1H27.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cartesian Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.